Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics Initiates Phase 1/2A Trial Of VB10.16

Sept 29 (Reuters) - Nykode Therapeutics ASA  NYKD.OL :
    * NYKODE THERAPEUTICS INITIATES PHASE 1/2A TRIAL OF VB10.16
IN
FIRST LINE HPV16-POSITIVE HEAD AND NECK CANCER
    * TRIAL EVALUATES VB10.16, COMPANY'S WHOLLY OWNED OFF--SHELF
THERAPEUTIC CANCER VACCINE CANDIDATE FOR HPV16-POSITIVE CANCERS
    * EVALUATES VB10.16 IN COMBINATION WITH MSD'S (MERCK & CO.,
RAHWAY, NJ, USA) PD-1 INHIBITOR KEYTRUDA® (PEMBROLIZUMAB)
    * MERCK WILL SUPPLY KEYTRUDA, WHILE NYKODE RETAINS ALL
COMMERCIAL
RIGHTS TO VB10.16 WORLDWIDE

Source text for Eikon:  ID:nObiyPGgRa 
Further company coverage:  NYKD.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Nykode Therapeutics ASA

See all news